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Antigen depot is not required for alum adjuvanticity
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ABSTRACT Alum adjuvants have been in continuous
clinical use for more than 80 yr. While the prevailing
theory has been that depot formation and the associ-
ated slow release of antigen and/or inflammation are
responsible for alum enhancement of antigen presen-
tation and subsequent T- and B-cell responses, this has
never been formally proven. To examine antigen per-
sistence, we used the chimeric fluorescent protein
EGFP, which allows assessment of antigen presenta-
tion in situ, using the Y-Ae antibody. We demonstrate
that alum and/or CpG adjuvants induced similar up-
take of antigen, and in all cases, GFP signal did not
persist beyond 24 h in draining lymph node antigen-
presenting cells. Antigen presentation was first detect-
able on B cells within 6–12 h of antigen administration,
followed by conventional dendritic cells (DCs) at 12–24
h, then finally plasmacytoid DCs at 48 h or later. Again,
alum and/or CpG adjuvants did not have an effect on
the magnitude or sequence of this response; further-
more, they induced similar antigen-specific T-cell acti-
vation in vivo. Notably, removal of the injection site and
associated alum depot, as early as 2 h after administra-
tion, had no appreciable effect on antigen-specific T-
and B-cell responses. This study clearly rules out a role
for depot formation in alum adjuvant activity.—Hutchi-
son, S., Benson, R. A., Gibson, V. B., Pollock, A. H.,
Garside, P., Brewer, J. M. Antigen depot is not required
for alum adjuvanticity. FASEB J. 26, 1272–1279 (2012).
www.fasebj.org
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Antigen depot is frequently cited as the principal
mechanism of action of vaccine adjuvants, in particular
clinically applicable adjuvants, such as alum. That de-
pot formation is important for alum adjuvant activity
was first proposed by Glenny et al. (1, 2) in 1925. Since
then, our understanding of microbial adjuvant activity
has progressed greatly, particularly in the past 15 yr,
with the description of Toll-like receptor (TLR) recog-
nition of microbial patterns, directly activating den-
dritic cell (DC) antigen presentation and T-cell activa-
tion (3). More recently, the induction of inflammation
by sensors of endogenous danger signals has been
proposed as a mechanism where nonmicrobial adju-
vants may have similar effects on DCs to enhance
subsequent T-cell responses (4). However, the role of
these mechanisms in alum adjuvant activity has re-
mained controversial (5, 6). In the absence of a defin-
itive mechanism of action, alum has remained in con-
stant clinical use for the past 80 yr, and throughout this
period, the depot theory of alum adjuvant activity has
persisted. However, no evidence exists in the literature
to demonstrate the importance, or otherwise, of the
antigen depot in the enhancement of antigen presen-
tation and subsequent primary T-cell and B-cell re-
sponses by alum adjuvants (7, 8). As there is an urgent
need for the development of new adjuvants with im-
proved immunogenicity and safety profiles, a clearer
understanding of the role that the depot plays in alum
adjuvant activity will clearly contribute to the rational
design of these important vaccine components.
MATERIALS AND METHODS
Mice
Homozygous DO11.10x4get mice were prepared from 4get (9)
and DO11.10 BALB/c TcR transgenic (tg) mice (10). Cell
suspensions from secondary lymphoid organs of DO11.10x4get
were labeled with the fluorescent dye Cell Tracker Orange
9-(4-(and 5)-chloromethyl-2-carboxyphenyl)-7-chloro-6-oxo-
1,2,2,4-tetramethyl-1,2-dihydropyrido[2,3-6]xanthene
(CMRA); Invitrogen, Paisley, UK; ref. 11], then 3  106 T cells
were transferred i.v. to 6- to 8-wk-old female BALB/c mice
(Harlan, Bicester, UK). Procedures were performed according
to the UK Home Office regulations.
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toid dendritic cell; TLR, Toll-like receptor.
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Antigens and adjuvants
BALB/c mice were immunized with chromatographically
purified chicken ovalbumin (OVA; Worthington Biochemi-
cal, Lakewood, NJ, USA), while C57BL/6 mice received
EGFP (12). Preparation of EGFP and associated experi-
mental protocols have been clearly described previously (13).
Adjuvants were a 1% alum suspension (Brenntag Biosector,
Frederikssund, Denmark), or 100 g/ml CpG (CpG-ODN
1826; Coley Pharmacuetical Group, Ottawa, ON, Canada) or
a combination of both. Mice received 100 l s.c., 50 l in the
footpad or 10 l in the ear pinna. Following ear pinna
administration, the injection site (0.5 cm2) was removed
under general anesthetic.
Flow cytometry
Cell suspensions were prepared from draining lymph nodes,
as described above, and analyzed using the appropriate
combinations of the following antibodies: CD4, KJ1.26, B220,
CD11c, CD69, CD62L, or Y-Ae (BD Biosciences, Oxford, UK)
in 100 l of FACS buffer (PBS, 2% fetal calf serum, and 0.05%
NaN3) containing Fc Block (2.4G2 hybridoma supernatant).
Antigen-presenting cell (APC) populations were identified as
B220-expressing B cells, CD11c-positive conventional DCs,
and B220/CD11c-expressing plasmacytoid DCs (pDCs), as
described previously (14, 15). Data were acquired on a
FACSCanto flow cytometer (BD Biosciences) and analyzed
using FlowJo software (Tree Star, Ashland, OR, USA).
Enzyme-linked immunosorbent assay (ELISA) and multiplex
bead cytokine analysis
Antigen-specific IgG1 and IgG2a titers were determined in
serum samples as described previously (16). Cytokine levels
were determined in supernatants from in vitro restimulated,
draining lymph node cell cultures by multiplex bead cytokine
analysis (Invitrogen), according to the manufacturer’s in-
structions.
Statistical analysis
Results are expressed as means  sd. Intergroup significance
was determined as appropriate, by Student’s 2-tailed unpaired
t test or 1-way ANOVA using Prism (GraphPad Software, La
Jolla, CA, USA). A value of P  0.05 was considered signifi-
cant.
RESULTS
Characterization of the adjuvant activity of alum and
CpG
We analyzed the kinetics of T-cell activation, division,
and differentiation in response to alum and compared
this with CpG adjuvants. Synthetic oligonucleotides
containing CpG motifs act via TLR9, expressed on a
number of cell types, to create a proinflammatory
Figure 1. Magnitude and kinetics of antigen-specific immune responses are comparable following immunization with alum or
CpG adjuvants. A) All adjuvants significantly increased the mean percentage of tg T cells (CD4KJ1.26) expressing CD69, at
d 1, 5, and 11. B) Mean percentage of tg T cells at the peak of expansion at d 5 postimmunization. C) Total number of tg T
cells expressing the IL-4 reporter was higher early (d 1; P0.05) with CpG/OVA compared with alum/OVA, although later (d
11) only alum/OVA or alum/OVA/CpG produced significant numbers of GFP-positive antigen-specific cells compared with
nonimmunized controls. D, E) Serum was taken from animals 14 d after immunization and assessed for the presence of anti-OVA
IgG1 (D) and anti-OVA IgG2a (E) by ELISA. Results are means  sd of 3 animals/group and are representative of 2
independent experiments. *P  0.05 vs. unimmunized control; 1-way ANOVA.
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environment (17). Although these two adjuvants are
proposed to have quite distinct mechanisms of action,
no difference in the magnitude and kinetics of antigen-
specific T-cell activation (Fig. 1A), as revealed by CD69
expression (18) and T-cell expansion (Fig. 1B) in the
draining lymph node, was observed following immuni-
zation. IL-4 production by antigen-specific T cells was
reported by GFP expression (9) and revealed a tran-
sient population of T cells induced by CpG adjuvant
(Fig. 1C), whereas the use of alum (or alum/CpG)
favored sustained IL-4 production past d 5 following
immunization. Previous studies have established that
the use of alum is associated with Th2 response gener-
ation (16), compared with CpG, which favors genera-
tion of Th1 responses (19). Antibody subclass data
confirmed this dichotomy, with alum promoting an
IgG1-dominated antibody response associated with Th2
induction, and CpG adjuvants boosting only IgG2a
responses that are dependent on Th1-derived IFN	
(16, 19). These responses were confirmed by analysis of
cytokine production by in vitro antigen-restimulated T
cells (data not shown).
Immunization with alum or CpG adjuvants gives rise
to a comparable distribution, magnitude, and
duration of antigen uptake and presentation in vivo
Given the similar kinetics of T-cell activation, we next
analyzed whether the different adjuvant prepara-
tions affected the acquisition of antigen and the mag-
nitude and duration of antigen presentation in vivo.
This was achieved by tracking the fluorescence signal
from the chimeric antigen EGFP, together with a
specific monoclonal antibody (Y-Ae; ref. 20) that rec-
ognizes presentation of the E peptide in the context
of I-Ab (12, 13), i.e., it recognizes what the T-cell
receptor sees (Supplemental Fig. S1). Antigen uptake
(GFP accumulation) occurred rapidly and decayed
simultaneously within each of the draining lymph node
APC populations analyzed; B cells (Fig. 2A), conven-
tional DCs (Fig. 2B), and plasmacytoid DCs (Fig. 2C).
Significantly, alum did not appear to affect the dynam-
ics of this acquisition and loss of signal, despite the
proposed formation of a slow-release depot of antigen.
B cells were the first APC population to become Y-Ae
positive, at 6–12 h following immunization with alum
adsorbed EGFP (Fig. 2D and Supplemental Fig. S2),
and choice of vaccine adjuvant did not appear to alter
the magnitude or duration of antigen presentation by B
cells. Conventional DCs presented antigen in a second,
discrete wave, between 12 and 24 h after alum/EGFP
administration (Fig. 2E and Supplemental Fig. S2), and
surprisingly, alum-induced depot formation did not
alter the kinetics or magnitude of antigen presentation
compared with either CpG or alum/CpG. With each of
the adjuvants tested, plasmacytoid DCs represented a
third discrete wave of antigen presentation in the
draining lymph node at 48 to 72 h following antigen
C C
C C
Figure 2. Immunization with alum or CpG adjuvants gives rise to a comparable distribution, magnitude, and duration of antigen
uptake and presentation in vivo. A–C) Duration and magnitude of antigen persistence were measured as the mean fluorescence
intensity (MFI) of EGFP protein detected at 6, 24, and 72 h postimmunization in B cells (A), CD11c DCs (B), and plasmacytoid
DCs (C). D–F) Duration and magnitude of antigen presentation were measured as the MFI of Y-Ae detection of the E-MHCII
complex at 1, 6, 12, 24, 36, 48, and 72 h postimmunization in B cells (D), CD11c DCs (E), and plasmacytoid DCs (F). Results
are means  sd of 3 animals/group and are representative of 3 independent experiments. *P  0.05 for EGFP/CpG vs.
EGFP/alum groups; 1-way ANOVA.
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immunization (Fig. 2F and Supplemental Fig. S2). It
was particularly striking that despite the proposed
depot formation by alum, there was no difference in
the kinetics of antigen uptake or presentation, or,
indeed, the APC populations engaged in these pro-
cesses in vivo, following immunization with antigen
prepared in any of the adjuvants.
Immunization with alum results in a short-term
persistence of antigen in comparison with CpG
adjuvant
Previous in vitro studies have associated antigen persis-
tence with enhanced T-cell activation and function (21)
and, in particular, Th2 responses (22). Consequently,
depot-forming adjuvants such as alum have been pro-
posed to act in this fashion (23). However, the studies
above suggest that alum does not affect the persistence
of antigen or antigen presentation by APC, nor the
magnitude and duration of T-cell expansion. As an
indirect, but sensitive, measure of persisting antigen
presentation in vivo, we transferred CMRA-labeled
(11), antigen-specific DO.11.10 transgenic T cells (10)
following immunization with antigen prepared in adju-
vants (Fig. 3A). These studies demonstrated T-cell
expansion (Fig. 3B), and division (Fig. 3C and Supple-
mental Fig. S3) could be detected when T cells were
transferred up to 5 d following administration of anti-
gen adsorbed to alum, but not together with CpG.
However, T-cell activation was no longer detectable
when cells were transferred 10 d following immuniza-
tion with any adjuvant formulation tested, indicating
that while the alum injection site can be observed for a
considerable period of time (2, 24), immunologically
recognized antigen only persists for a short period of
time.
Removal of the depot does not alter the magnitude
and kinetics of antigen-specific immune responses
following alum immunization
Alum, and the associated injection site reaction, remain
focal and discrete following subcutaneous administra-
tion, for example, in the footpad or ear (Fig. 4A).
Consequently, it was relatively straightforward to di-
rectly address the importance of the depot by removing
the injection site at various times following immuniza-
tion and evaluating the effect of ablation on the
resulting immune response. Immediate removal of the
injection site after administration of antigen and adju-
vant prevented any detectable activation of antigen-
specific T cells, as measured by CD69 expression (Fig.
4B), T-cell expansion (Fig. 4C), division (Fig. 4D), and
IL-4 production (revealed by GFP expression; Fig. 4E
and ref. 9). However, much to our surprise, removal of
the injection site as early as 2 h following antigen/
adjuvant administration had no effect on these param-
eters (Fig. 4B–E). Further experiments removed the
injection site 2 h after antigen/adjuvant administration
and analyzed the resulting antibody response 14 d later
(Figs. 4F–I). These studies demonstrated that alum-
induced IgG1 titers were unaffected by injection site
ablation (Fig. 4F) and confirmed the lack of Th1-
associated IgG2a production previously observed (Fig.
4H). Interestingly, the IgG2a response induced by
CpG/alum adjuvants did appear to be partially depen-
dent on the intact injection site (Fig. 4I). In vitro
restimulation and analysis of cytokines at 14 d after
immunization confirmed that injection site ablation
did not significantly affect the magnitude and profile of
T-cell cytokine production (data not shown).
Removal of the depot does not alter the magnitude
or phenotype of recall memory responses following
alum immunization
While primary T- and B-cell responses were unaffected
by removal of the alum depot, it remained possible that
the depot and associated prolonged release of antigen
affects recall memory responses. We therefore exam-
ined the effect of injection site ablation on the ability of
mice to mount antigen-specific, recall immune re-
sponses (Fig. 5A). Surprisingly, injection site ablation
induced a small increase in OVA-specific IgG1 titer at 1
wk postchallenge (Fig. 5C), although this was transient,
and no effect of ablation on IgG1 responses was ob-
served at other time points (Fig. 5D, E). Consistent with
the results from Fig. 4, injection site ablation did not
affect the inability of alum/OVA-immunized mice to
produce Th1-associated, IgG2a responses.
Figure 3. Immunization with alum in comparison with CpG
adjuvant results in a short-term persistence of antigen. A)
Timeline outlining experiment protocol. B) Mean percent-
age of tg T cells at 5 d following immunization of mice that
received an adoptive transfer of tg T cells 1, 5, 10, 14, and 28 d
previously. C) Tg T cells (CD4KJ1.26) were counted and
then assessed for CFSE division by flow cytometry. Results are
means  sd of 3 animals/group and are representative of 2
independent experiments. *P  0.05 for OVA/alum vs.
OVA/CpG; 1-way ANOVA.
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Depot ablation does not alter the magnitude and
duration of antigen uptake and presentation in vivo
following immunization with alum
We therefore determined the influence of injection site
ablation on the characteristic distribution of antigen
uptake and presentation in vivo using the EGFP/Y-Ae
system described above. The uptake of GFP by B cells,
conventional DCs, and plasmacytoid DCs peaked at 6 h
and decreased thereafter, as shown above (Fig. 2A–C),
and this was not affected by injection site ablation 2 h
after EGFP administration (data not shown). Notably,
injection site ablation did not affect the magnitude of
kinetics of antigen presentation by B cells (Fig. 6A) or
conventional DCs (Fig. 6B) compared with intact mice,
although there was a minor though significant reduc-
tion in presentation by plasmacytoid DCs, 72 h after
immunization with alum (Fig. 6C).
DISCUSSION
In the current study, we have demonstrated that alum
adjuvants fail to sustain antigen availability and presen-
tation in draining lymph nodes, which would be incon-
sistent with a depot-forming mechanism of action.
Irrespective of adjuvant used, antigen uptake by APC
populations (B cells, conventional DCs, and plasmacy-
toid DCs) in the draining lymph node occurred rapidly
and decayed simultaneously. Similar kinetics have pre-
viously been described with soluble antigen (12), and
here, we show that alum did not appear to affect the
dynamics of this acquisition and loss of signal, despite
the proposed formation of a slow-release depot of
antigen. Significantly, recent in vitro data demonstrated
that in the presence of interstitial fluid, elution of
antigen from alum occurs rapidly, within 1–2 h (25),
suggesting that the majority of antigen administered in
alum will travel to the draining lymph node in a soluble
rather than adsorbed form.
Following uptake of antigen, we then analyzed pre-
sentation of antigen, directly ex vivo, using the E/Y-Ae
system (12, 13). Despite the simultaneous acquisition of
antigen by APCs noted above, presentation of antigen
occurred in 3 discrete waves; B cells presented antigen
within 6 h, conventional DCs after 12–24 h, and finally
plasmacytoid DCs 
48 h following antigen administra-
tion. Previous studies have demonstrated similar kinet-
ics of B-cell and conventional DC antigen presentation
in vivo following soluble antigen administration (12).
Surprisingly, the choice of vaccine adjuvant did not
appear to alter the magnitude or duration of antigen
presentation, despite the ability of CpG adjuvants to
directly activate APCs (26–28). Therefore, despite the
Figure 4. Ear ablation does not alter the magnitude and
kinetics of antigen-specific immune responses following
alum immunization. A) Histological analysis demonstrates
a discrete subcutaneous depot of alum up to 24 h after
injection. Injection sites were subsequently removed imme-
diately, or at 2, 6, or 24 h postimmunization. B–E) Effect of
injection site removal on mean percentage of tg T cells
expressing CD69 (B), mean percentage of tg T cells in
draining lymph nodes (C), mean percentage of tg T cells
(CD4KJ1.26) that divided (D), and mean percentage of
tg T cells (CD4KJ1.26) expressing GFP, a marker of IL4 production, at 5 d postimmunization (E). F–I) Effect of injection
site removal 2 h postimmunization on titers of anti-OVA IgG1 after immunization with OVA/alum (F), alum/CpG and titers
of anti-OVA IgG2a (G), OVA/alum (H), and alum/CpG (I). Results are means  sd of 3 animals/group and are
representative of 2 independent experiments. *P0.05 for intact vs. removed; 1-way ANOVA.
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supposed formation of an antigen depot by alum, the
kinetics and cellular distribution of antigen uptake and
presentation in vivo, appeared unaffected by the choice
of adjuvant. These results are, therefore, consistent
with previous studies demonstrating rapid elution of
antigen from alum in vitro (25) and in vivo (29), directly
questioning whether alum acts as an antigen depot at
all. These results were broadly confirmed by studies
demonstrating that adoptive transfer of antigen-specific
transgenic T cells 10 d or longer after antigen/adjuvant
treatment failed to respond. There were, however,
some differential effects of adjuvants in maintaining
this response, with alum prolonging T-cell responses to
antigen compared with CpG. Likewise, antigen presen-
tation by pDCs at 72 h was significantly higher when
using alum adjuvant compared with CpG.
Nevertheless, these studies do not rule out a role for
other adjuvant-driven, depot-associated events, such as
injection site inflammation that could affect T-cell
activation. Therefore, to directly address this, we re-
moved the injection site from 2 to 24 h following
administration of antigen and adjuvant. These data
demonstrated that the alum injection site is dispensable
for adjuvant activity within 2 h of administration, clearly
ruling out any role for an antigen depot. Previous
studies have demonstrated that removal of the alum
injection site 7 d after immunization does not affect the
production or maintenance of subsequent antibody
responses (30). We have, therefore, extended these
studies to show that the depot is not responsible for
adjuvant-driven enhancement of the T-cell or the B-cell
response. More significantly, the 7-d ablation studies
described by Holt (30) allowed ample time for the
development of a primary T-cell and subsequent B-cell
response, which have been shown to initiate within 48 h
of antigen injection (31). Therefore, in contrast to
previous work, our current study more directly ad-
dresses the issue of the role of depot in the enhance-
ment of primary T-cell responses by adjuvants. How-
ever, it remained possible that prolonged release of
antigen from an alum depot would contribute more to
memory than acute primary responses (32). We there-
fore analyzed the effect of depot ablation on the ability
of mice to mount subsequent antigen-specific recall
responses. Surprisingly, removal of the injection site
had no effect on the magnitude or phenotype of the
recall antibody response. Given the role of antigen in
the maintenance of memory responses (32), this result
strongly suggests that alum does not form an antigen
depot at all. Interestingly, studies with Freund’s adju-
vants have also demonstrated that injection site abla-
tion in a similar 2-h window does not affect induction of
disease in an adjuvant-induced arthritis model (33).
The speed at which the depot becomes redundant
was also surprising given the various adjuvant-host cell
interactions that are thought to occur in these tissues in
order to drive adjuvant enhancement of primary T-cell
responses. First, inflammatory cells recruited into the
site of inoculation of depot and inflammatory adjuvants
have been thought to play an important role in medi-
ating adjuvant activity (8, 34). Second, adjuvant-in-
duced inflammation is thought to evoke activation of
Figure 5. Ear ablation following OVA/alum immunization does not alter the magnitude or phenotype of recall memory
responses. A) Mice were immunized with OVA adsorbed to alum, and the injection site was ablated 2 h later. After 2 wk,
OVA-specific responses were recalled in control (intact) and ablated mice by immunization with heat-aggregated OVA (HAO).
B–E) IgG1 responses were detectable prior to (B) and at 1 wk (C), 2 wk (D) or 3 wk (E) following challenge. Injection site
ablation induced a small increase in IgG1 titer at 1 wk postchallenge; no effect of ablation was observed at other time points.
F–I) Injection site ablation did not affect the inability of alum/OVA immunized mice to produce IgG2a responses at 1 wk (G),
2 wk (H) or 3 wk (I) postchallenge, compared to prechallenge (F). Results are means  sd of 5 animals/group. ***P  0.01.
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DCs at the injection site and consequently increase DC
migration to draining lymph nodes (27, 35), and these
migratory DCs are required for T-cell activation (12,
36). While alum is known to induce injection site
inflammation (6, 8), clearly further studies are re-
quired to confirm when this process occurs, its role in
adjuvant activity, and specifically, whether alum in-
duces a migratory DC population and the role that
these cells play in mediating adjuvant activity. Analysis
of antigen presentation following alum/antigen injec-
tion site ablation produced a similar duration, se-
quence, and magnitude of antigen presentation as
intact controls. The most likely explanation for this
response is that antigen released from alum at the
injection site moves to the draining lymph node as
soluble antigen and is presented by lymph node resi-
dent rather than migratory DCs. However, this hypoth-
esis remains to be formally tested.
In summary, our studies clearly demonstrate that
antigen depot does not play an important role in alum
adjuvant activity, demonstrating that this particular
hypothesis, untested for over 80 yr, does not explain
how these clinically important vaccine adjuvants func-
tion. This finding has two main implications in vaccine
research. First, the tissue reactions induced by the alum
depot that persist for several days, such as pain, redness
and swelling, do not appear to be required for adjuvant
activity. Second, in the absence of conclusive evidence
for alternative mechanisms of action (8), it highlights
that there are other processes involved in alum adju-
vant activity, knowledge of which will clearly facilitate
the rational design of novel and more effective vaccine
adjuvants that are urgently required.
This work was funded by grants from the UK Biotechnol-
ogy and Biological Sciences Research Council and The Well-
come Trust.
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